Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment.
Hematopoietic progenitor cell transplantation is often associated with severe mucosal toxicity. The need for parenteral analgesics and parenteral nutrition are evidence of the severity of the problem in individual patients. However, the increased risk for systemic infection related to bacteremia associated with the breakdown of mucosal barriers is a significant cause of morbidity and mortality as well. There is a multitude of grading scales, demonstrating the lack of consensus among clinicians in this area. Multiple agents have been used prophylactically and therapeutically to address mucositis. While efforts have been less successful in the past, the advent of newer agents including amifostine, keratinocyte growth factor, transforming growth factor beta and interleukin-11 provides hope that this toxicity will be significantly decreased in the near future.
Filicko
J
J
Hematologic Malignancies, Blood & Marrow Transplant Program, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA.
Lazarus
H M
HM
Flomenberg
N
N
D004999:Amifostine / Q000627:therapeutic use; D006801:Humans; D017370:Interleukin-11 / Q000627:therapeutic use; D009092:Mucous Membrane / Q000473:pathology*; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D016212:Transforming Growth Factor beta / Q000627:therapeutic use
D017370:Interleukin-11; D016212:Transforming Growth Factor beta; D004999:Amifostine